• SPX
  • $5,739.10
  • 0.76 %
  • $43.16
  • DJI
  • $42,043.59
  • 0.21 %
  • $89.35
  • N225
  • $38,937.54
  • -1 %
  • -$395.20
  • FTSE
  • $8,190.61
  • -1.36 %
  • -$113.01
  • IXIC
  • $18,131.94
  • 1.16 %
  • $208.04
PMV Pharmaceuticals, Inc. (PMVP) Stock Price, News & Analysis

PMV Pharmaceuticals, Inc. (PMVP) Stock Price, News & Analysis

Currency in USD Disclaimer

$1.50

-$0

(0%)

Day's range
$1.48
Day's range
$1.51
50-day range
$1.4
Day's range
$1.75
  • Country: US
  • ISIN: US69353Y1038
52 wk range
$1.18
Day's range
$6.55
  • CEO: Dr. David H. Mack Ph.D.
  • Website: Visit Site


We are preparing, please wait

Analyst Ratings

Key Stats

Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.

Stock Score/grades

The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company

  • Altman Z Score 0.05
  • Piotroski Score 4.00
  • Grade Buy
  • Symbol (PMVP)
  • Company PMV Pharmaceuticals, Inc.
  • Price $1.50
  • Changes Percentage (0%)
  • Change -$0
  • Day Low $1.48
  • Day High $1.51
  • Year High $6.55

PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. The company's lead product candidate is PC14586, a small molecule that corrects a p53 protein containing the Y220C mutation and restores wild-type p53 function. It is also developing mutant p53 programs, including Wild-type p53 Induced-Phosphatase, R282W, and R273H, as well as other p53 hotspot mutations. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013. PMV Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Cranbury, New Jersey.

  • Last Earnings
  • Ex-Dividend for 5/16 Dividend
  • Dividend Payable
  • Today N/A
  • Next Earnings (Estimated) 11/07/2024
  • Fiscal Year End N/A

  • Average Stock Price Target $29.00
  • High Stock Price Target $36.00
  • Low Stock Price Target $5.00
  • Potential Upside/Downside N/A
  • Consensus Rating Sell
  • Rating Score (0-4) N/A
  • Research Coverage N/A

  • EPS (Most Recent Fiscal Year) -$1.32
  • Trailing P/E Ratio -1.26
  • Forward P/E Ratio -1.26
  • P/E Growth -1.26
  • Net Income $-68,960,000

Income Statement

Quarterly

Annual

Enter your phone number to get Breaking News Updates

Stay ahead with instant updates! Enter your phone number for breaking news alerts, ensuring you're always in the know with the latest developments.


We are preparing, please wait

Portfolio Sync Solutions

Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced

GET STARTED
Portfolio Sync Solutions
×
New Alert

Select an alert type

Choose sentiment spike or mentions spike or both to receive email alerts and app notification for the selected stock.
Note: Please be aware that you will receive an email only once a day, around 8:00 AM (EST), in the event of any spike.
In future if you don't want to receive any email then delete stocks added into alert section.

New Alert

Setup alert

×

Premium Content

This content is only available for premium members. Please become a paid member to access.

Download App

Currently, memberships can only be purchased through the app.

×

Log In


or

download app using google store Continue with Google download app using apple Continue with Apple

Email Verification

An email with a verification code has been sent to your email address.

Welcome to StockNews!

Create Your Account

Email Verification

An email with a verification code has been sent to your email address.